Literature DB >> 21937284

Urethra low-dose tunnels: validation of and class solution for generating urethra-sparing dose plans using inverse planning simulated annealing for prostate high-dose-rate brachytherapy.

J Adam M Cunha1, Jean Pouliot, Vivian Weinberg, Alice Wang-Chesebro, Mack Roach, I-Chow Hsu.   

Abstract

PURPOSE: Urethral dose is related to severity of genitourinary toxicity in patients treated with brachytherapy for prostate cancer. This work describes a dose planning method that uses inverse planning to create a low-dose tunnel around the urethra and presents a class solution to achieve this additional dose sparing of the urethra.
METHODS: Fifteen patients on the Radiation Therapy Oncology Group (RTOG) 0321 protocol were treated for prostate cancer with a high-dose-rate brachytherapy dose boost to an external beam radiation treatment regimen. All were treated with 9.5Gy for each of the two fractions after 45Gy of the external beam radiation. The inverse-planning algorithm, inverse planning simulated annealing (IPSA), was used to create both the standard RTOG protocol (SRP) plan for treatment and the a posteriori urethra dose sparing (UDS) plan consisting of a dose tunnel along the urethra. Both plans maintained the protocol parameters: prostate V(100) (volume receiving 100% of prescribed dose)>90% and bladder and rectum V(75)<1 cm(3). In the SRP plans, the urethra surface was optimized to receive <125% of the prescription dose and in the UDS plans <100%. Dose-volume histograms for the clinical treatment volume, bladder, rectum, penile bulb, and urethra for both plans are compared using a paired sample t test with significance claimed for probability values<0.05.
RESULTS: UDS planning reduced the urethra V(100) from 88% to 58% on average (p<0.01) and the V(125) from 3.3% to 0.2% (p < 0.01). Bladder and rectum V(75) were maintained at <1 cm(3) and not significantly different between plans. Prostate coverage was maintained per protocol at V(100)>90%, with mean for the SRP V(100)=93% versus UDS plan V(100)=90%. Prostate D(90) for SRP was 104% versus UDS plan D(90)=101%. For all patients, the UDS achieved a dose tunnel surrounding the length of the intraprostatic urethra. The class solution for generating UDS is presented.
CONCLUSIONS: A urethral sparing-focused planning solution using IPSA reduces mean urethral dose by 34%, as compared with IPSA-generated plans based on the RTOG 0321 protocol. This is done while maintaining prostate coverage and critical structure dose. This technique can be applied to all patients in whom urethra toxicity is of particular concern.
Copyright © 2012 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21937284     DOI: 10.1016/j.brachy.2011.07.009

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

1.  Dosimetric analysis of radiation therapy oncology group 0321: the importance of urethral dose.

Authors:  I-Chow Hsu; Daniel Hunt; William Straube; Jean Pouliot; Adam Cunha; Devan Krishnamurthy; Howard Sandler
Journal:  Pract Radiat Oncol       Date:  2013-03-29

2.  Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.

Authors:  I-Chow Hsu; Joseph P Rodgers; Katsuto Shinohara; James Purdy; Jeff Michalski; Mack Roach; Eric Vigneault; Robert A Ivker; Rodger M Pryzant; Michael Kuettel; Daniel Taussky; Gary S Gustafson; Adam Raben; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-10       Impact factor: 8.013

3.  Comparison of Oncentra® Brachy IPSA and graphical optimisation techniques: a case study of HDR brachytherapy head and neck and prostate plans.

Authors:  Michael G Jameson; Lucy Ohanessian; Vikneswary Batumalai; Virendra Patel; Lois C Holloway
Journal:  J Med Radiat Sci       Date:  2015-05-20

4.  Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.

Authors:  Iván Henríquez; Gemma Sancho; Asunción Hervás; Benjamin Guix; Joan Pera; Cristina Gutierrez; Oscar Abuchaibe; Rafael Martínez-Monge; Alejandro Tormo; Alfredo Polo
Journal:  Radiat Oncol       Date:  2014-04-30       Impact factor: 3.481

5.  Template guided transperineal saturation biopsy of the prostate: lessons for focal and urethra-sparing high-dose-rate brachytherapy for localized prostate cancer.

Authors:  Sergey Nikolaevich Novikov; Sergey Vasilevich Kanaev; Roman Vladimirovich Novikov; Nikolay Dmitrievich IIlin; Anna Sergeevna Artemieva; Alexnder Olegovich Ivantcov; Evgeniy Alexandrovich Piskunov; Mariya Yurievna Gotovchikova
Journal:  J Contemp Brachytherapy       Date:  2016-04-19

6.  Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Authors:  Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu
Journal:  J Contemp Brachytherapy       Date:  2018-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.